ZBIO ▼ -0.2% - Zenas BioPharma, Inc. $ZBIO - Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 Zenas BioPharma's stock was down 0.2% today despite announcing that it will present data on obexelimab, its treatment for IgG4-related disease, at two major medical conferences later this year. The company's minimal decline suggests the market had already priced in expectations for these presentations, or investors are awaiting the actual data disclosures before reassessing the stock. 22-SEP-2026 07:05 AM ET